Scholarlink

<p>This study designed and evaluated a chitosan nanoparticle-based mucosal vaccine (CS-CKS9-MEV-DCpep-NPs) targeting M cells and dendritic cells against <i>Brucella</i>. From four immunogenic outer membrane proteins (OMP10, Omp25, Omp31, BtpB), 41 specific epitope peptides were screened and optimized via bioinformatics and ELISPOT for high antigenicity and safety. The dual-targeting strategy uses CKS9 to enhance M cell-mediated antigen uptake and DCpep, together with CS-NPs, to activate DCs and promote their maturation. This coordinates cDC1, cDC2, and pDC subsets, inducing CD8⁺ and CD4⁺ T cell responses and strengthening Th1-biased immunity against intracellular bacteria. The vaccine activates mucosal (sIgA), humoral (IL-21, memory B cells), and cellular (Th1/CTL, central memory T cells) immunity. It significantly reduces bacterial load and tissue damage, offering comprehensive protection. Compared with conventional vaccines, this oral nanovaccine provides high safety, precise targeting, and multi-dimensional immune activation, representing a novel strategy for brucellosis control.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dual-targeting oral nanoparticle mucosal vaccine against brucella infection: co-targeting M cells and dendritic cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月15日

查看全文
  • Tingting Tian,
  • Xinxin Qi,
  • Juan Shi,
  • Kaiyu Shang,
  • Huidong Shi,
  • Jiarui Luo,
  • ZhengLong Chai,
  • Chuang Li,
  • Jianbing Ding,
  • Yuejie Zhu,
  • Fengbo Zhang

摘要

This study designed and evaluated a chitosan nanoparticle-based mucosal vaccine (CS-CKS9-MEV-DCpep-NPs) targeting M cells and dendritic cells against Brucella. From four immunogenic outer membrane proteins (OMP10, Omp25, Omp31, BtpB), 41 specific epitope peptides were screened and optimized via bioinformatics and ELISPOT for high antigenicity and safety. The dual-targeting strategy uses CKS9 to enhance M cell-mediated antigen uptake and DCpep, together with CS-NPs, to activate DCs and promote their maturation. This coordinates cDC1, cDC2, and pDC subsets, inducing CD8⁺ and CD4⁺ T cell responses and strengthening Th1-biased immunity against intracellular bacteria. The vaccine activates mucosal (sIgA), humoral (IL-21, memory B cells), and cellular (Th1/CTL, central memory T cells) immunity. It significantly reduces bacterial load and tissue damage, offering comprehensive protection. Compared with conventional vaccines, this oral nanovaccine provides high safety, precise targeting, and multi-dimensional immune activation, representing a novel strategy for brucellosis control.

Graphical Abstract